Results 131 to 140 of about 397,523 (260)
Sickle Cell Leg Ulcer Extending to the Achilles Tendon [PDF]
Asma S, Boğa B, Kaçmaz M.
europepmc +1 more source
Hong Kong Poison Information Centre: Annual report 2022
Abstract Background The Hong Kong Poison Information Centre (HKPIC) has been providing consultation services to healthcare professionals and collecting epidemiological data on poisoning in Hong Kong since 2005. Objective To analyse and report the poisoning data from HKPIC in 2022.
Tin Yat Anthony Chow +4 more
wiley +1 more source
Cost Effectiveness of Venous Leg Ulcer Healing Using Muscle Pump Activation. [PDF]
Stacey MC, Harris C, Loney A, Corke G.
europepmc +1 more source
ABSTRACT Background and Aims Wound care is a critical component of postoperative and chronic disease management, yet rising supply costs, inconsistent insurance coverage, and patient‐level barriers can complicate care in outpatient and home settings.
Joseph D. Quick +8 more
wiley +1 more source
Validation and Clinimetric Properties of the Persian Version of the Leg Ulcer Measurement Tool. [PDF]
Hajilo Q +4 more
europepmc +1 more source
A meta-review of the impact of compression therapy on venous leg ulcer healing. [PDF]
Patton D +12 more
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle‐specific kinase (MuSK) antibody‐positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis. Method We report a very late‐onset MuSK‐MG case complicated by lung infection and acute heart failure,
Tianjiao Duan +3 more
wiley +1 more source
Platelet-Rich Plasma in a Refractory Venous Leg Ulcer Following Multiple Failed Skin Grafts. [PDF]
Seretis K +4 more
europepmc +1 more source
Psychometric Properties of the Traditional Chinese Version of the Venous Leg Ulcer Quality of Life Questionnaire. [PDF]
Lin HC, Fang CL, Hsu CH, Fan JY.
europepmc +1 more source
Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Albert Qin +20 more
wiley +1 more source

